Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 27 June 2018 | By Zachary Brennan
China’s State Drug Administration (SDA, formerly known as the CFDA) announced yesterday that for the first time since 2014, a major overhaul of its medical device regulations has taken root. “It is timely in that U.S. tariffs are anticipated to be levied at 25% duty on many of the medical devices shipped from China to the U.S.,” consultants from China Med Device wrote. China Med Device CEO Grace Fu explained to Focus that this is a draft document and interested persons can submit feedback by 24 July. The final version should be coming before the year’s end, she said. According to the device consultancy, 12 articles were newly added to the regulations, two were deleted and 39 modified. Among the major changes include allowing the registration holder to be independent of the manufacturer and relaxing the requirements on accepting overseas clinical trial data. Certain devices will also be able to win conditional approval to expedite their entry to the market. In addition, class II domestic device approvals have been moved from the provincial regulators to the national one. And according to Chinese consultants from Med Device, provincial and local regulators “will establish career inspectors like the regional FDA inspectors in the U.S.” Fu added that this is a "huge" change as CFDA did not have career inspectors prior to the drafting of these new regulations. She also said there will be more postmarket studies conducted in China and more contract manufacturers. Text (in Chinese) Updated with comment from Grace Fu.